Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Raiola

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Bone Marrow Transplantation|June 26, 2007
Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplantD Vicente, T Lamparelli, F Gualandi, et al.
Bone Marrow Transplantation|August 5, 2000
Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding studyS Bregante, S Bertilson, E Tedone, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|August 13, 2018
Visceral leishmaniasis in hematopoietic cell transplantation: Case report and review of the literatureP Tatarelli, G Fornaro, V Del Bono, et al.
British Journal of Haematology|August 6, 2000
Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of ageA M Raiola, M T Van Lint, T Lamparelli, et al.
Bone Marrow Transplantation|September 1, 2009
Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor typeA Bacigalupo, M Soraru, A Dominietto, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 14, 2003
Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplantsA Bacigalupo, T Lamparelli, F Gualandi, et al.
European Journal of Neurology|May 18, 2020
Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumabG Boffa, C Lapucci, E Sbragia, et al.
Bone Marrow Transplantation|April 15, 2003
Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusionsA M Raiola, M T Van Lint, M Valbonesi, et al.
Bone Marrow Transplantation|June 4, 2015
Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an updateA Bacigalupo, A Dominietto, A Ghiso, et al.
Bone Marrow Transplantation|October 14, 2014
DLI after haploidentical BMT with post-transplant CYA Ghiso, A M Raiola, F Gualandi, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Bone Marrow Transplantation|June 26, 2007
Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplantD Vicente, T Lamparelli, F Gualandi, et al.
Bone Marrow Transplantation|August 5, 2000
Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding studyS Bregante, S Bertilson, E Tedone, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|August 13, 2018
Visceral leishmaniasis in hematopoietic cell transplantation: Case report and review of the literatureP Tatarelli, G Fornaro, V Del Bono, et al.
British Journal of Haematology|August 6, 2000
Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of ageA M Raiola, M T Van Lint, T Lamparelli, et al.
Bone Marrow Transplantation|September 1, 2009
Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor typeA Bacigalupo, M Soraru, A Dominietto, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 14, 2003
Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplantsA Bacigalupo, T Lamparelli, F Gualandi, et al.
European Journal of Neurology|May 18, 2020
Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumabG Boffa, C Lapucci, E Sbragia, et al.
Bone Marrow Transplantation|April 15, 2003
Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusionsA M Raiola, M T Van Lint, M Valbonesi, et al.
Bone Marrow Transplantation|June 4, 2015
Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an updateA Bacigalupo, A Dominietto, A Ghiso, et al.
Bone Marrow Transplantation|October 14, 2014
DLI after haploidentical BMT with post-transplant CYA Ghiso, A M Raiola, F Gualandi, et al.
Pageof 4